关注我们
ZH
ZH

我的生活+的主要目标之一是帮助人们预防新的HIV和其他STI，丙型肝炎和结核病病历的产生。

该应用程序有助于建立医生和HIV感染者之间的匿名沟通。 它可以让您创建简单易行的服药时间表，并设置隐藏和个性化的提醒。

全部新闻 / 十月 2016

归档

✕
26 十月 2016
4717
Dolutegravir and central nervous system side-effects: abacavir, older age increase the risk

Dolutegravir and central nervous system side-effects: abacavir, older age increase the risk

Insomnia, dizziness, headache and other central nervous system side-effects are occurring more frequently with everyday use of dolutegravir than clinical trials had suggested, and are most likely to occur in women, people over 60 and people starting abacavir at the same ...
26 十月 2016
4234
A Cas9 Ribonucleoprotein Platform for Functional Genetic Studies of HIV-Host Interactions in Primary Human T Cells

A Cas9 Ribonucleoprotein Platform for Functional Genetic Studies of HIV-Host Interactions in Primary Human T Cells

New genetic tools are needed to understand the functional interactions between HIV and human host factors in primary cells said Sell Reports. A group of american scientists developed a method to edit the genome of primary CD4+ T cells by electroporation of CRISPR/Cas9 ribonucleoproteins ...
25 十月 2016
3810
Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies

Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies

Considerable scope exists to vary the physical and chemical properties of nanoparticles, with subsequent impact on biological interactions; however, no accelerated process to access large nanoparticle material space is currently available, hampering the development of new ...
24 十月 2016
4347
Lack of epidemiologic indicators increases risk of missed HIV diagnosis

Lack of epidemiologic indicators increases risk of missed HIV diagnosis

Patients who do not have epidemiologic indicators of HIV are more likely to have a history of missed presentation, are less likely to get tested for HIV, and are more likely to neglect HIV symptoms, according to results of a cross-sectional study published in PLoS One
24 十月 2016
4471
Two thirds of oral prep-using MSM would switch to long-term shots

Two thirds of oral prep-using MSM would switch to long-term shots

One third of men who have sex with men (MSM) using daily oral PrEP for a year or more would “definitely switch” to a long-acting PrEP shot every 3 months, while another third would “probably switch,” according to results of a 90-man survey. Hispanic and nonwhite men were ...
24 十月 2016
4398
New Hep C panviral not better than earlier drugs?

New Hep C panviral not better than earlier drugs?

German researchers looking for proof of the effectiveness of the drug combo sofosbuvir/velpatasvir (epclusa/gilead sciences) found the studies submitted by the manufacturer proved it offered “a hint of added benefit” in only two of ten subindications. The direct-acting ...
21 十月 2016
4589
Controlling the HIV epidemic: ambitious funding, expanded workforce, innovations and micro-focus needed

Controlling the HIV epidemic: ambitious funding, expanded workforce, innovations and micro-focus needed

Advocates who seek to end AIDS by 2030 should be ready to call on Hillary Clinton to massively increase United States support for the Global Fund to Fight AIDS and the US President’s Emergency Plan for AIDS Relief (PEPFAR) if she wins next month’s US presidential election, ...
21 十月 2016
4668
Insurers accused of discriminating against HIV patients

Insurers accused of discriminating against HIV patients

The health law prohibits insurers from discriminating against people with serious illnesses, but some marketplace plans sidestep that taboo by making the drugs that people with HIV need unavailable or unaffordable, complaints filed recently (PDF) with the Department of Health ...
21 十月 2016
6462
Norway to provide free HIV-preventing PrEP drugs to at-risk gay men

Norway to provide free HIV-preventing PrEP drugs to at-risk gay men

Norway is sending a bold message to the world by becoming the first country to make HIV-preventing PrEP drugs available through its National Health Service. It is a result of two years of lobbying by HIV Norway – the national organisation for people living with HIV.
20 十月 2016
5211
Second case report of PrEP failure due to drug-resistant virus

Second case report of PrEP failure due to drug-resistant virus

A PrEP user in New York City has become HIV positive with virus that is resistant to Truvada and other antiretroviral drugs, the HIV Research for Prevention (HIVR4P 2016) conference in Chicago heard today. This is only the second such case that has been reported, highlighting ...
我们在此网站上使用cookies以增强您的浏览体验。
继续浏览网页即表示您同意我们在网站上使用默认的cookies设置。